faculty

Peter Nelson

pnelson@fhcrc.org

Fred Hutch, 

Cancer Biology

Developmental Biology, Stem Cells & Aging

Gene Expression, Cell Cycle & Chromosome Biology

Genetics and Genomics of Cancer

Faculty Contact Information

Building: Thomas Room: D4-109 Box: D4-100 Phone: 206-667-3377

Lab Information

Location: Fred Hutchinson Cancer Research Center Building: Thomas Building Room: D4-100 Box: D4-100 Phone: 206-667-3498 Alt Phone: 206-667-3377

Accepting Students For:

Rotation, Autumn
Rotation, Spring
Rotation, Summer
Rotation, Winter
Permanent

Publications

The following publications were retrieved from PubMed:

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Feb 12;

EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H.

EMBO J. 2019 Feb 5;

Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy.

Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM.

Nat Cell Biol. 2019 Feb; 2(21)238-250

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Jan 21;

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec; 12(24)1887-1898

Research Summary

We study several inter-related aspects of cancer biology. We seek to identify and understand the role of key somatic genomic alterations that drive cancer development, metastasis (with organ tropism), and therapy resistance. A second area of focus involves determining influences of the tumor microenvironment on cancer cell behavior. A third area of focus centers on determining the roles of hormones and nuclear hormone receptors as lineage oncogenes, with a particular emphasis on cancer of the prostate, the most common cancer affecting men.